APA: American Psychiatric Association Annual Meeting

Providers who treat young people with psychosis must navigate a host of issues unique to this population, including confidentiality and consent rules, the role of the family, and support from schools, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.

Data presented at the 175th Annual Meeting of the American Psychiatric Association (APA) support the potential of the investigational drug ALKS 3831 to provide the antipsychotic efficacy of olanzapine without the associated weight gain, said Adam Simmons, director of clinical program management, Alkermes. He also discussed the timing of when the data might be filed with the FDA.

Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients. Simmons spoke about data presented at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.

Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, said that technological solutions like artificial intelligence can help identify and monitor signs of mental illness so patients can be connected with the help they need.

Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.

Olanzapine is an effective antipsychotic medication, but the associated weight gain is the number one cause of discontinuation, explained Adam Simmons, director of clinical program management, Alkermes, during an interview at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California. An investigational drug, ALKS 3831, aims to mitigate the weight gain associated with olanzapine.

David Kingdon, MD, professor of mental health care delivery, University of Southampton, outlined some future avenues for research on the use of cognitive behavioral therapy (CBT) in psychosis, including the benefits of “worry periods” and studies on sleep.

Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.

Cognitive behavioral therapy (CBT) can be used in conjunction with medication and community care to treat psychosis and incorporate families and caregivers into the treatment process, according to David Kingdon, MD, professor of mental health care delivery, University of Southampton.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo